CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

Its architect's daughter has cystic fibrosis—and benefits from a "miracle drug" backed by an agency he's attacking.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by analysts at Barclays from $435.00 to $467.00 in a research report issued to clients and investors on ...